NO996182D0 - Krystallinsk roksifiban - Google Patents

Krystallinsk roksifiban

Info

Publication number
NO996182D0
NO996182D0 NO996182A NO996182A NO996182D0 NO 996182 D0 NO996182 D0 NO 996182D0 NO 996182 A NO996182 A NO 996182A NO 996182 A NO996182 A NO 996182A NO 996182 D0 NO996182 D0 NO 996182D0
Authority
NO
Norway
Prior art keywords
crystalline roxifiban
roxifiban
crystalline
Prior art date
Application number
NO996182A
Other languages
English (en)
Other versions
NO996182L (no
Inventor
Michael B Maurin
Philip Ma
David J Meloni
Jaan A Pesti
Lucius Thomas Rossano
Randall K Ward
Jianguo Yin
Lin-Hua Zhang
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NO996182D0 publication Critical patent/NO996182D0/no
Publication of NO996182L publication Critical patent/NO996182L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
NO996182A 1997-06-16 1999-12-14 Krystallinsk roksifiban NO996182L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4963397P 1997-06-16 1997-06-16
US4971297P 1997-06-16 1997-06-16
US8027898P 1998-04-01 1998-04-01
PCT/US1998/012367 WO1998057939A1 (en) 1997-06-16 1998-06-12 Crystalline roxifiban

Publications (2)

Publication Number Publication Date
NO996182D0 true NO996182D0 (no) 1999-12-14
NO996182L NO996182L (no) 1999-12-14

Family

ID=27367578

Family Applications (1)

Application Number Title Priority Date Filing Date
NO996182A NO996182L (no) 1997-06-16 1999-12-14 Krystallinsk roksifiban

Country Status (18)

Country Link
US (1) US6306886B1 (no)
EP (1) EP0991630A1 (no)
JP (1) JP2002504153A (no)
KR (1) KR20010013790A (no)
CN (1) CN1259940A (no)
AR (2) AR016070A1 (no)
AU (1) AU751198B2 (no)
CA (1) CA2294047A1 (no)
EA (1) EA200000028A1 (no)
EE (1) EE9900573A (no)
HR (1) HRP980291A2 (no)
HU (1) HUP0004755A3 (no)
IL (1) IL132618A0 (no)
NO (1) NO996182L (no)
NZ (1) NZ502077A (no)
PL (1) PL337612A1 (no)
SK (1) SK166699A3 (no)
WO (1) WO1998057939A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207065T1 (de) * 1997-08-08 2001-11-15 Aventis Pharma Gmbh Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid
US6908907B2 (en) * 2002-04-22 2005-06-21 El-Naggar Mawaheb M. Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
EP2576523B1 (en) * 2010-05-27 2016-01-13 E. I. du Pont de Nemours and Company Crystalline form of 4-[5 - [3 -chloro-5 -(trifluoromethyl)phenyl] -4,5 -dihydro-5 -(trifluoromethyl)-3 - isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naphthalenecarboxamide
EP2710355B2 (en) * 2011-05-17 2023-01-11 ZETACUBE S.r.l. Method of detecting polymorphs using synchrotron radiation
GB2515783B (en) * 2013-07-03 2018-07-11 Rotam Agrochem Int Co Ltd Process for preparing clomazone, a form and use of the same
KR20240037628A (ko) 2022-09-15 2024-03-22 문혜경 그래핀이 함유된 고강도 내열 안경렌즈 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ES2154326T3 (es) * 1993-11-24 2001-04-01 Du Pont Pharm Co Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol.

Also Published As

Publication number Publication date
HUP0004755A2 (hu) 2001-07-30
CA2294047A1 (en) 1998-12-23
CN1259940A (zh) 2000-07-12
NO996182L (no) 1999-12-14
SK166699A3 (en) 2001-09-11
KR20010013790A (ko) 2001-02-26
HUP0004755A3 (en) 2002-10-28
HRP980291A2 (en) 1999-04-30
AR023840A2 (es) 2002-09-04
PL337612A1 (en) 2000-08-28
US6306886B1 (en) 2001-10-23
EA200000028A1 (ru) 2000-08-28
AU8071998A (en) 1999-01-04
IL132618A0 (en) 2001-03-19
JP2002504153A (ja) 2002-02-05
EP0991630A1 (en) 2000-04-12
AR016070A1 (es) 2001-06-20
NZ502077A (en) 2002-03-01
EE9900573A (et) 2000-08-15
WO1998057939A1 (en) 1998-12-23
AU751198B2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
NO20003131D0 (no) Krystallinsk teriparatid
ATE250583T1 (de) Substituierte 3-cyanochinoline
ATE233060T1 (de) Zahnbürste
ATE537728T1 (de) Zahnbürste
DE69815089D1 (de) Selbstaufrichtende zahnbürste
ATE231349T1 (de) Zahnbürste
DE59806063D1 (de) Zahnbürste
EP0953464A4 (en) LOUVRE
DE59813487D1 (de) Substituierte 4-benzoyl-pyrazole
DE69714228D1 (de) Kristalline metallophosphate
DE69809270D1 (de) Zahnbürste
NO996182D0 (no) Krystallinsk roksifiban
DK0960100T3 (da) Substituerede 4-benzoyl-pyrazoler
DE69614821D1 (de) Geschalteter Taktgeber
KR980000103U (ko) 자라사육기
DE59807877D1 (de) Substituierte 4-benzoyl-pyrazole
ID24079A (id) Aminoheteroksiklilamida tersubstitusi
NO983650D0 (no) Krystallinske progestagener
DE59810960D1 (de) Substituierte phenyluracile
KR980000415U (ko) 치솔
ATE266645T1 (de) Substituierte phenyluracile
KR970020599U (ko) 부착식 칫솔
KR980000413U (ko) 칫솔
KR970015998U (ko) 치솔
KR970053294U (ko) 칫솔

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application